Literature DB >> 18198000

Assessment of humoral and cell-mediated immunity against Bordetella pertussis in adolescent, adult, and senior subjects in Italy.

G Gabutti1, M Bergamini, P Bonanni, M Guido, D Fenoglio, A Giammanco, L Sindoni, C Zotti, V Boddi, F Bamfi, R Severini, A Bechini, S Boccalini, P Crovari.   

Abstract

Humoral and cell-mediated immunity (CMI) against B. pertussis was assessed in a sample of adolescent, adult and senior subjects distributed in five different geographical areas in Italy. Most (99.1%) subjects had IgG anti-pertussis toxin (PT) antibodies exceeding the minimum detection level [> or = 2 ELISA units (EU)/ml]. There were no significant differences between the genders; 6.2% samples recorded titres > or = 100 EU/ml. CMI was positive [stimulation index (SI) > or = 5] against PT in 39.0% of all samples. This study suggests that B. pertussis continues to circulate in age groups that have been previously considered to be uninvolved in the circulation of this pathogen and that adolescent and adult pertussis boosters may be of value in these populations. Nevertheless, over the last 10 years, large increases in vaccination coverage rates have contributed to reduce the spread of the aetiological agent, especially in the immunized population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18198000      PMCID: PMC2870754          DOI: 10.1017/S0950268807000192

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  42 in total

1.  Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis.

Authors:  H E de Melker; F G Versteegh; M A Conyn-Van Spaendonck; L H Elvers; G A Berbers; A van Der Zee; J F Schellekens
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

Review 2.  Bordetella pertussis, molecular pathogenesis under multiple aspects.

Authors:  C Locht; R Antoine; F Jacob-Dubuisson
Journal:  Curr Opin Microbiol       Date:  2001-02       Impact factor: 7.934

Review 3.  How to make sense of pertussis immunogenicity data.

Authors:  P Olin; H O Hallander; L Gustafsson; E Reizenstein; J Storsaeter
Journal:  Clin Infect Dis       Date:  2001-12-15       Impact factor: 9.079

Review 4.  Immunity to Bordetella pertussis.

Authors:  K H Mills
Journal:  Microbes Infect       Date:  2001-07       Impact factor: 2.700

Review 5.  Pertussis of adults and infants.

Authors:  C H Wirsing von König; S Halperin; M Riffelmann; N Guiso
Journal:  Lancet Infect Dis       Date:  2002-12       Impact factor: 25.071

6.  European Sero-Epidemiology Network: standardisation of the assay results for pertussis.

Authors:  A Giammanco; A Chiarini; P A C Maple; N Andrews; R Pebody; N Gay; R M Olander; F Fivet-Groyne; S Baron; A Tischer; S Swidsinski; J Schellekens; E Reizenstein
Journal:  Vaccine       Date:  2003-12-08       Impact factor: 3.641

7.  Sero-epidemiology of Bordetella pertussis in England and Wales.

Authors:  A Nardone; R G Pebody; P A C Maple; N Andrews; N J Gay; E Miller
Journal:  Vaccine       Date:  2004-03-12       Impact factor: 3.641

8.  Serological correlates of immunity to Bordetella pertussis.

Authors:  E L Hewlett; S A Halperin
Journal:  Vaccine       Date:  1998-12       Impact factor: 3.641

Review 9.  Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration.

Authors:  M Campins-Martí; H K Cheng; K Forsyth; N Guiso; S Halperin; L M Huang; J Mertsola; G Oselka; J Ward; C H Wirsing von König; F Zepp
Journal:  Vaccine       Date:  2001-12-12       Impact factor: 3.641

10.  Pertussis is a frequent cause of prolonged cough illness in adults and adolescents.

Authors:  L D Senzilet; S A Halperin; J S Spika; M Alagaratnam; A Morris; B Smith
Journal:  Clin Infect Dis       Date:  2001-05-21       Impact factor: 9.079

View more
  6 in total

1.  Decline of IgG pertussis toxin measured in umbilical cord blood, and neonatal and early infant serum.

Authors:  L C S Smallenburg; N A van Welie; L H Elvers; J C M van Huisseling; P F M Teunis; F G A Versteegh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-04-23       Impact factor: 3.267

2.  Hospitalizations for pertussis in Italy, 1999-2009: analysis of the hospital discharge database.

Authors:  Giovanni Gabutti; Maria Cristina Rota; Bernardo Bonato; Roberta Pirani; Giuliana Turlà; Alessandro Cucchi; Alessandra Cavallaro
Journal:  Eur J Pediatr       Date:  2012-07-13       Impact factor: 3.183

Review 3.  Pertussis.

Authors:  Giovanni Gabutti; Chiara Azzari; Paolo Bonanni; Rosa Prato; Alberto E Tozzi; Alessandro Zanetti; Gianvincenzo Zuccotti
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 4.  Recommended vaccinations for asplenic and hyposplenic adult patients.

Authors:  Paolo Bonanni; Maddalena Grazzini; Giuditta Niccolai; Diana Paolini; Ornella Varone; Alessandro Bartoloni; Filippo Bartalesi; Maria Grazia Santini; Simonetta Baretti; Carlo Bonito; Paola Zini; Maria Teresa Mechi; Fabrizio Niccolini; Lea Magistri; Maria Beatrice Pulci; Sara Boccalini; Angela Bechini
Journal:  Hum Vaccin Immunother       Date:  2017-02       Impact factor: 3.452

5.  Vaccination coverage in healthcare workers: a multicenter cross-sectional study in Italy.

Authors:  C Genovese; I A M Picerno; G Trimarchi; G Cannavò; G Egitto; B Cosenza; V Merlina; G Icardi; D Panatto; D Amicizia; A Orsi; C Colosio; C Marsili; C Lari; M A R Palamara; F Vitale; A Casuccio; C Costantino; A Azara; P Castiglia; A Bianco; A Currà; G Gabutti; A Stefanati; F Sandri; C Florescu; M Marranzano; G Giorgianni; V Fiore; A Platania; I Torre; A Cappuccio; A Guillari; L Fabiani; A R Giuliani; A Appetiti; V LA Fauci; A Squeri; R Ragusa; R Squeri
Journal:  J Prev Med Hyg       Date:  2019-03-29

Review 6.  Pertussis: a review of disease epidemiology worldwide and in Italy.

Authors:  Giovanni Gabutti; Maria Cristina Rota
Journal:  Int J Environ Res Public Health       Date:  2012-12       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.